Advertisement


Justin F. Gainor, MD, on Non–Small Cell Lung Cancer: Clinical Activity and Tolerability of Selective RET Inhibitor

2019 ASCO Annual Meeting

Advertisement

Justin F. Gainor, MD, of Massachusetts General Hospital, discusses updated findings from the ARROW study in which BLU-667, a selective RET inhibitor, demonstrated clinical activity and tolerability in patients with advanced RET fusion–positive non–small cell lung cancer (Abstract 9008).



Related Videos

Lung Cancer
Immunotherapy

Edward B. Garon, MD, on Advanced Non–Small Cell Lung Cancer: KEYNOTE-001 Trial on Pembrolizumab

Edward B. Garon, MD, of the David Geffen School of Medicine at the University of California, Los Angeles, discusses long-term survival data on patients with advanced non–small cell lung cancer treated with pembrolizumab and those with PD-L1 expressed in at least half of their tumor cells (Abstract LBA9015).

Issues in Oncology
Immunotherapy

Lee S. Schwartzberg, MD, FACP: 2019 Update on the ACCC Immuno-Oncology Institute: Using Immunotherapy in the Community Setting

Lee S. Schwartzberg, MD, of the West Cancer Center, reports on this past year’s progress of the ACCC initiative to speed adoption of immunotherapeutics in community practices.

Lung Cancer

Luis G. Paz-Ares, MD, PhD, on Small Cell Lung Cancer: Efficacy and Safety of Lurbinectedin

Luis G. Paz-Ares, MD, PhD, of Hospital Universitario 12 de Octubre, discusses study findings on the second-line use of lurbinectedin in patients with both resistant and sensitive small cell lung cancer (Abstract 8506).

Lymphoma
Immunotherapy

Jason Westin, MD, on Diffuse Large B-Cell Lymphoma: Rituximab, Lenalidomide, and Ibrutinib Prior to Chemotherapy

Jason Westin, MD, of The University of Texas MD Anderson Cancer Center, discusses findings of the Smart Start study on the chemotherapy-free combination of rituximab, lenalidomide, and ibrutinib in newly diagnosed diffuse large B-cell lymphoma (Abstract 7508).

Lung Cancer
Immunotherapy

David J. Kwiatkowski, MD, PhD, on Non–Small Cell Lung Cancer: Neoadjuvant Immunotherapy for Resectable Disease

David J. Kwiatkowski, MD, PhD, of Brigham and Women’s Hospital and Dana-Farber Cancer Institute, discusses an interim analysis and biomarker data from a multicenter study showing that 19% of patients with NSCLC had a major pathologic response to preoperative treatment with atezolizumab (Abstract 8503).

Advertisement

Advertisement




Advertisement